

## CONFIDENTIAL COMMERCIAL INFORMATION EXEMPT FROM DISCLOSURE UNDER THE FREEDOM OF INFORMATION ACT

September 23, 2015

## To Whom It May Concern:

You requested a current list of the platforms on which all of our tests are running as of September 22, 2015. We are providing that information to you under separate cover. Additionally, the following is the list of the Laboratory Developed Tests (LDTs) that Theranos tested on Theranos device, also called Theranos Sample Processing Units (TSPUs), along with the time periods when those tests were run. Theranos recently received FDA clearance for its Theranos System – including the device, the Theranos Sample Collection Device (including the nanotainers) and other components of the system –, and plans to bring these units live again in the lab as 510k-cleared analyzers, rather than LDTs, once additional clearances are obtained.

As we explained in person, Theranos changes the platforms on which it runs tests from time to time. The decision to move testing off of TSPUs and onto other platforms in this case was a business decision to transition to the manufacturing quality systems to QSR compliance under FDA guidelines and does not reflect on the reliability or accuracy of any platform.

Similar Marie	. 1	Dage.	40 4.40	40 30	a management of the co
Theranos	has neve	er comm	rerctally	distribute	d a TSPU.

Š	San	ě.		
M	Test	Initial	End	The state of the s
į	Vit D	11/6/2013	3/10/2015	
N	TSH	11/7/2013	2/4/2015	N
	FT4	11/11/2013	2/4/2015	
	TPSA	11/11/2013	6/25/2015	
	TT3	2/12/2014	2/4/2015	
İ	TT4	2/12/2014	2/4/2015	
	TST	3/19/2014	3/10/2015	
Ì	HCG	5/9/2014	1/19/2015	
	SHBG	7/28/2014	6/25/2015	
	VB12	8/12/2014	3/6/2015	
Ì	Estradiol	9/25/2014	12/18/2014	
	Prolactin	9/25/2014	12/18/2014	( ) The state of t
•			THERANO	S CONFIDENTIAL

Confidential

THPFM0002422856 US-REPORTS-0023789